These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 48414)

  • 1. Virologic and immunologic studies of human prostatic carcinoma.
    Dmochowski L; Maruyama K; Ohtsuki Y; Seman G; Bowen JM; Newton WA; Johnson DE
    Cancer Chemother Rep; 1975; 59(1):17-31. PubMed ID: 48414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Search for oncogenic viruses in human prostate cancer.
    Dmochowski L; Ohtsuki Y; Seman G; Maruyama K; Knesek JE; East JL; Bowen JM; Yoshida H; Johnson DE
    Cancer Treat Rep; 1977; 61(2):119-27. PubMed ID: 68817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic and immunologic studies of human prostatic carcinoma.
    Mickey DD; Stone KR; Stone MP; Paulson DF
    Cancer Treat Rep; 1977; 61(2):133-8. PubMed ID: 68819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of oncornaviruses in carcinoma of the prostate.
    McCombs RM
    Cancer Treat Rep; 1977; 61(2):131-2. PubMed ID: 68818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrastructural studies of human prostatic neoplasia.
    Ohtsuki Y; Seman G; Maruyama K; Bowen JM; Johnson DE; Dmochowski L
    Cancer; 1976 May; 37(5):2295-305. PubMed ID: 56984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma.
    Festuccia C; Teti A; Bianco P; Guerra F; Vicentini C; Tennina R; Villanova I; Sciortino G; Bologna M
    Oncol Res; 1997; 9(8):419-31. PubMed ID: 9436195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
    Purnell DM; Heatfield BM; Trump BF
    Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
    Festuccia C; Vincentini C; di Pasquale AB; Aceto G; Zazzeroni F; Miano L; Bologna M
    Oncol Res; 1995; 7(3-4):131-8. PubMed ID: 8555646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
    Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
    J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells.
    Festuccia C; Bologna M; Vicentini C; Tacconelli A; Miano R; Violini S; Mackay AR
    Int J Cancer; 1996 Oct; 69(5):386-93. PubMed ID: 8900372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cathepsin B in angiogenesis of human prostate: an immunohistochemical and immunoelectron microscopic analysis.
    Sinha AA; Gleason DF; Staley NA; Wilson MJ; Sameni M; Sloane BF
    Anat Rec; 1995 Mar; 241(3):353-62. PubMed ID: 7538734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia.
    Polnaszek N; Kwabi-Addo B; Wang J; Ittmann M
    Prostate; 2004 Jun; 60(1):18-24. PubMed ID: 15129425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D receptor, HER-2 polymorphisms and risk of prostate cancer in men with benign prostate hyperplasia.
    Tayeb MT; Clark C; Haites NE; Sharp L; Murray GI; McLeod HL
    Saudi Med J; 2004 Apr; 25(4):447-51. PubMed ID: 15083213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.
    Okamoto M; Lee C; Oyasu R
    Cancer Res; 1997 Jan; 57(1):141-6. PubMed ID: 8988055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of immunohistochemical detection of VEGF in prostate carcinoma.
    Kamath A; Helie M; Bifulco CB; Li WW; Concato J; Jain D
    Appl Immunohistochem Mol Morphol; 2009 May; 17(3):227-32. PubMed ID: 19098681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
    Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
    Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples.
    Gravina GL; Mancini A; Ranieri G; Di Pasquale B; Marampon F; Di Clemente L; Ricevuto E; Festuccia C
    Int J Oncol; 2013 Jun; 42(6):2116-22. PubMed ID: 23589051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do men with prostate abnormalities (prostatitis/benign prostatic hyperplasia/prostate cancer) develop immunity to spermatozoa or seminal plasma?
    Hoover P; Naz RK
    Int J Androl; 2012 Aug; 35(4):608-15. PubMed ID: 22321000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.
    Hansson J; Bjartell A; Gadaleanu V; Dizeyi N; Abrahamsson PA
    Prostate; 2002 Sep; 53(1):50-9. PubMed ID: 12210479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
    Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
    Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.